Patient with mass effective brain tumor that undergo non-invasive intracranial pressure measurement

Tumor, Brain

Intracranial Pressure Increase

Non-invasive measurement of intracranial pressure in patients with mass effective brain Tumors

Non-invasive measurement of intracranial pressure

Kantonsspital Aarau

non_invasive_aICP_Tumor

Non-Invasive Measurement of Absolute Intracranial Pressure in Patients With Mass Effective Brain Tumors

The primary outcome is the non-invasive, absolute intracranial pressure (aICP) before brain tumor surgery, as determined by the "NON-INVASIVE ICP ABSOLUTE VALUE METER" in mmHG.

The secondary outcome is to demonstrate correlation between increased aICP and clinical and radiological signs.

Javier Fandino, MD

Glioblastoma Multiforme

Anaplastic Glioma

Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).
BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle.

Temodar and O6-Benzylguanine (BG)

The Preston Robert Tisch Brain Tumor Center at DUKE

astrocytoma/nausea

non_invasive_aICP_Tumor

Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma

The most complete medicinal herbs database backed by science